Ipamorelin
Women's HealthWomen's-health applications of Ipamorelin require explicit attention to cyclical hormonal context, contraceptive and pregnancy considerations, and — for users in perimenopause or postmenopause — integration with HRT. Highly selective GHSR1a agonist Triggers pulsatile GH release from somatotrophs without engaging the cortisol or prolactin axis at therapeutic doses. Synergistic with GHRH analogues (CJC-1295) because the two pathways converge on the same pituitary cell.. Dosing at 200-300 mcg 1-3x daily subq via subq with cycle-phase-aware tracking is the standard protocol for premenopausal users.
Key Takeaways
Female-physiology lens: Ipamorelin response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause. Mechanism: Highly selective GHSR1a agonist. Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default. Female dose: 200-300 mcg 1-3x daily subq via subq; cycle-phase tracking for 1-2 cycles. Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.
Highly selective GHSR1a agonist. Triggers pulsatile GH release from somatotrophs without engaging the cortisol or prolactin axis at therapeutic doses. Synergistic with GHRH analogues (CJC-1295) because the two pathways converge on the same pituitary cell. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. Ipamorelin's contribution to each varies; the subsections below work through these in turn.
Fertility and reproductive considerations
Ipamorelin's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.
Bone density and cardiovascular signalling
Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Ipamorelin's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.
Perimenopause and menopause integration
For women in the perimenopausal or post-menopausal window, Ipamorelin is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.
For bone density in female users, Ipamorelin is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
Perimenopause is one of the dimensions on which women track Ipamorelin response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.
In the perimenopausal window, Ipamorelin for cardiovascular (female) produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
For sleep in female users, Ipamorelin is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 200-300 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 120-300 mcg | 4–6 weeks initial cycle |
| Women's Health focus | SubQ | 200-300 mcg | 1-3x daily SubQ |
| Maintenance phase | SubQ | 140-300 mcg | Ongoing with periodic pauses |
Dose timing for Ipamorelin is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
Ipamorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.
- Ipamorelin + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Ipamorelin's mechanism in female physiology protocols.
- Ipamorelin + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Ipamorelin's mechanism in female physiology protocols.
- Ipamorelin + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Ipamorelin's mechanism in female physiology protocols.
- Ipamorelin + Epithalon: Identified by Khavinson in St. Pairs naturally with Ipamorelin's mechanism in female physiology protocols.
Cleanest side-effect profile among GHRPs. Mild flushing possible. Site reactions occasional.
Lens-specific safety considerations for female physiology use of Ipamorelin: Cleanest side-effect profile among GHRPs. Mild flushing possible. Site reactions occasional. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | Women's Health |
| Oxytocin | Posterior pituitary nonapeptide | ~1-6 min plasma; CNS longer | The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
Can I use Ipamorelin alongside HRT?
Can I use Ipamorelin during pregnancy or while trying to conceive?
Best monitoring labs for female users?
Is Ipamorelin appropriate during perimenopause?
What should I look for in Ipamorelin sourcing and quality?
What is the evidence base for Ipamorelin?
Start a Ipamorelin Protocol
Alukard provides physician-supervised women's health protocols with GMP-certified Ipamorelin and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
Get ProtocolQuick Facts
- Molecular weight
- 712 Da
- Sequence length
- 5 aa
- Half-life
- ~2 hr
- WADA
- Banned (S2)
- FDA
- Unapproved
- Research
- Phase II in GH deficiency; off-label use widespread
Stack Partners
All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Ipamorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Female Physiology Protocol for Ipamorelin
Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
HIPAA Compliant · GMP Certified · Physician Supervised